Data from Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218

Autor: Andrew B. Nixon, Michael J. Birrer, Robert A. Burger, Wei Deng, Matthew Boente, Keiichi Fujiwara, Jamie N. Bakkum-Gamez, Heidi Gray, David M. O'Malley, Krishnansu S. Tewari, Robert S. Mannel, Herbert I. Hurwitz, Heather A. Lankes, J. Chris Brady, Mark D. Starr, Yingmiao Liu, Alexander B. Sibley, David Tritchler, Kouros Owzar, Kirsten Bell Burdett, Angeles Alvarez Secord

Purpose:GOG-0218, a double-blind placebo-controlled phase III trial, compared carboplatin and paclitaxel with placebo, bevacizumab followed by placebo, or bevacizumab followed by bevacizumab in advanced epithelial ovarian cancer (EOC). Results demons

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6c46078192db3ae0cddc44cbfc81d043
https://doi.org/10.1158/1078-0432.c.6528411.v1

Supplementary Data Legends from Predictive Blood-Based Biomarkers in Patients with Epithelial Ovarian Cancer Treated with Carboplatin and Paclitaxel with or without Bevacizumab: Results from GOG-0218

Autor: Andrew B. Nixon, Michael J. Birrer, Robert A. Burger, Wei Deng, Matthew Boente, Keiichi Fujiwara, Jamie N. Bakkum-Gamez, Heidi Gray, David M. O'Malley, Krishnansu S. Tewari, Robert S. Mannel, Herbert I. Hurwitz, Heather A. Lankes, J. Chris Brady, Mark D. Starr, Yingmiao Liu, Alexander B. Sibley, David Tritchler, Kouros Owzar, Kirsten Bell Burdett, Angeles Alvarez Secord

Legends

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13a83f6259c9f2a856f3b2d3b4515392
https://doi.org/10.1158/1078-0432.22473081.v1

Recurrent ovarian cancer. Effective radiotherapeutic palliation after chemotherapy failure

Autor: Rachelle M. Lanciano, W. Michael Hunter, Matthew Boente, Robert F. Ozols, B S John Ladazack, Benjamin W. Corn

Publikováno v: Cancer. 74:2979-2983

Background. Recurrent ovarian cancer after frontline chemotherapy is incurable; however, palliation of focal lesions often is needed to alleviate symptoms. Because published response rates to palliative irradiation (RT) among patients failing cisplat

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::79458a3311d0172c2fa3bc308313e352
https://doi.org/10.1002/1097-0142(19941201)74:11<2979::aid-cncr2820741114>3.0.co

Abstract 4712: Evidence of clinical efficacy of the combination of flavopiridol (Alvocidib) and cisplatin in platin-resistant ovarian and primary peritoneal carcinoma: Phase 2 trial MC0261

Autor: Keith Christopher Bible, Prema P. Peethambaram, Ann L. Oberg, William J. Maples, David L. Groteluschen, Matthew Boente, Jill K. Burton, Leigh C. Gomez-Dahl, Jennifer D. Tibodeau, Crescent R. Isham, Andrea K. Kukla, Kalli J. Voll, Alexander D. Colevas, John Wright, L Austin Doyle, Charles Erlichman, Mayo Phase Consortium

Publikováno v: Cancer Research. 71:4712-4712

Background: Based upon preclinical synergy and prior phase 1 study results, the clinical efficacy of flavopiridol combined with cisplatin was assessed in patients with recurrent ovarian and primary peritoneal cancers. Methods: A two cohort phase 2 tr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e3a0473141cf6f02b2f82109596cda08
https://doi.org/10.1158/1538-7445.am2011-4712

Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.

Autor: Burger RA; Robert A. Burger, Fox Chase Cancer Center, Philadelphia, PA; Mark F. Brady, GOG Statistical and Data Center, Buffalo, NY; Michael A. Bookman, Arizona Cancer Center, Tucson, AZ; Bradley J. Monk, University of California at Irvine, Orange, CA; Joan L. Walker, University of Oklahoma, Oklahoma City, OK; Howard D. Homesley, Wake Forest University Medical Center, Winston-Salem, NC; Jeffrey Fowler, Ohio State University, Columbus, OH; Benjamin E. Greer, University of Washington Medical Center, Seattle, WA; Matthew Boente, Minnesota Oncology Hematology, Minneapolis, MN; Gini F. Fleming, University of Chicago, Chicago, IL; Peter C. Lim, Center of Hope at Renown Regional Medical Center, Reno, NV; Stephen C. Rubin, University of Pennsylvania Cancer Center, Philadelphia, PA; Noriyuki Katsumata, Saitama Medical University/International Medical Center-GOG Japan, Saitama, Japan; and Sharon X. Liang, North Shore University Hospital, Manhasset, NY., Brady MF, Bookman MA, Monk BJ, Walker JL, Homesley HD, Fowler J, Greer BE, Boente M, Fleming GF, Lim PC, Rubin SC, Katsumata N, Liang SX

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2014 Apr 20; Vol. 32 (12), pp. 1210-7. Date of Electronic Publication: 2014 Mar 17.